110 related articles for article (PubMed ID: 12926141)
1. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Ohta S; Fuse H; Fujiuchi Y; Nagakawa O; Furuya Y
Anticancer Res; 2003; 23(3C):2945-50. PubMed ID: 12926141
[TBL] [Abstract][Full Text] [Related]
2. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of urokinase-type plasminogen activator in human gliomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Am J Pathol; 1995 Jul; 147(1):114-23. PubMed ID: 7604873
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
5. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Skelly MM; Troy A; Duffy MJ; Mulcahy HE; Duggan C; Connell TG; O'Donoghue DP; Sheahan K
Clin Cancer Res; 1997 Oct; 3(10):1837-40. PubMed ID: 9815571
[TBL] [Abstract][Full Text] [Related]
8. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
Kim SJ; Shiba E; Taguchi T; Watanabe T; Tanji Y; Kimoto Y; Izukura M; Takai SI
Anticancer Res; 1997; 17(2B):1373-8. PubMed ID: 9137501
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
Zhao W; Wang X; Qu B; Huang X; Wang H
Chin Med J (Engl); 2002 May; 115(5):702-4. PubMed ID: 12133538
[TBL] [Abstract][Full Text] [Related]
13. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.
Eandi JA; Yang JC; Evans CP
Biochem Biophys Res Commun; 2001 Nov; 288(3):521-7. PubMed ID: 11676474
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.
Weiss TW; Simak R; Kaun C; Rega G; Pflüger H; Maurer G; Huber K; Wojta J
Anticancer Res; 2011 Oct; 31(10):3273-8. PubMed ID: 21965736
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
17. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.
Yamada Y; Nakamura K; Aoki S; Taki T; Naruse K; Matsubara H; Tobiume M; Zennami K; Katsuda R; Honda N
BJU Int; 2007 Jan; 99(1):189-95. PubMed ID: 17034504
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
20. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
